Patient-reported outcomes with insulin degludec/liraglutide (IDegLira) vs basal-bolus therapy in patients with type 2 diabetes: DUAL VII trial

被引：0
|
作者：
Jodar, E. [1 ]
Doshi, A. [2 ]
Gouet, D. [3 ]
Oviedo, A. [4 ,5 ]
Rodbard, H. W. [6 ]
Tentolouris, N. [7 ]
Busk, A. K. [8 ]
Basse, A. [8 ]
Billings, L. K. [9 ,10 ]
机构：
[1] Univ Europea Madrid, Univ Hosp Quiron Salud, Madrid, Spain
[2] PrimeCare Med Grp, Houston, TX USA
[3] La Rochelle Hosp, La Rochelle, France
[4] Santojanni Hosp, Buenos Aires, DF, Argentina
[5] Cenudiab, Buenos Aires, DF, Argentina
[6] Endocrine & Metab Consultants, Rockville, MD USA
[7] Univ Athens, Sch Med, Athens, Greece
[8] Novo Nordisk AS, Soborg, Denmark
[9] NorthShore Univ Hlth Syst Evanston, Chicago, IL USA
[10] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
804
引用
收藏
页码：S370 / S370
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of insulin degludec/liraglutide (IDegLira) vs basal-bolus therapy in patients with type 2 diabetes: DUAL VII trial
    Billings, L. K.
    Doshi, A.
    Gouet, D.
    Oviedo, A.
    Rodbard, H. W.
    Tentolouris, N.
    Gron, R.
    Halladin, N.
    Jodar, E.
    DIABETOLOGIA, 2017, 60 : S366 - S366
  • [2] Patient-Reported Outcomes (PROs) in Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus (BB) Therapy in Patients (Pts) with Type 2 Diabetes (T2D): DUAL VII Trial
    Billings, Liana K.
    Doshi, Ankur
    Gouet, Didier
    Oviedo, Alejandra
    Rodbard, Helena W.
    Tentolouris, Nikolaos
    Kirstine Busk, Anne
    Basse, Amaury
    Jodar, Esteban
    DIABETES, 2017, 66 : LB32 - LB32
  • [3] Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus (BB) Therapy in Patients with Type 2 Diabetes (T2D): DUAL VII Trial
    Billings, Liana K.
    Doshi, Ankur
    Gouet, Didier
    Oviedo, Alejandra
    Rodbard, Helena W.
    Tentolouris, Nikolaos
    Gron, Randi
    Halladin, Natalie
    Jodar, Esteban
    DIABETES, 2017, 66 : A36 - A36
  • [4] The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial
    Billings, Liana K.
    Agner, Bue F. Ross
    Altuntas, Yuksel
    Gron, Randi
    Halladin, Natalie
    Klonoff, David C.
    Tentolouris, Nikolaos
    Jodar, Esteban
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2021, 15 (03): : 636 - 645
  • [5] Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial
    Billings, Liana K.
    Doshi, Ankur
    Gouet, Didier
    Oviedo, Alejandra
    Rodbard, Helena W.
    Tentolouris, Nikolaos
    Gron, Randi
    Halladin, Natalie
    Jodar, Esteban
    DIABETES CARE, 2018, 41 (05) : 1009 - 1016
  • [6] Efficacy of IDegLira vs. Basal-Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics
    Billings, Liana K.
    Klonoff, David C.
    Tentolouris, Nikolaos
    Gron, Randi
    Halladin, Natalie
    Jodar, Esteban
    DIABETES, 2018, 67
  • [7] Insulin degludec/liraglutide (IDegLira) improves patient-reported outcomes in subjects with type 2 diabetes uncontrolled on insulin glargine plus metformin: DUALV
    Lingvay, I.
    Manghi, F. C. Perez
    Garcia-Hernandez, P. A.
    Norwood, P.
    Jarlov, H.
    Kongso, J. H.
    Brod, M.
    DIABETOLOGIA, 2015, 58 : S400 - S400
  • [8] Evaluation of the Short-Term Cost-Effectiveness of Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus Therapy in the USA
    Billings, Liana K.
    Mocarski, Michelle
    Slothuus, Ulla
    Hunt, Barnaby
    Valentine, William
    Jodar, Esteban
    DIABETES, 2017, 66 : A254 - A255
  • [9] Insulin degludec/liraglutide (IDegLira) improves patient-reported outcomes in subjects with Type 2 diabetes inadequately controlled on insulin glargine (IGlar) plus metformin: DUAL V study
    Viljoen, A.
    Brod, M.
    Perez Manghi, F. C.
    Garcia-Hernandez, P. A.
    Norwood, P.
    Jarlov, H.
    Kongso, J. H.
    Lingvay, I.
    DIABETIC MEDICINE, 2016, 33 : 65 - 65
  • [10] Insulin Degludec: Reduction of Hypoglycemia during Basal-Bolus Therapy in Patients with Diabetes Mellitus Type 1 or 2
    Luedemann, J.
    Merker, L.
    Milek, K.
    Kaiser, M.
    Wilhelm, B.
    DIABETOLOGIE UND STOFFWECHSEL, 2013, 8 (01) : 35 - 42
12345